Smartphone-powered trial backs J&J's Invokana for heart fail...

Johnson & Johnson's SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of sympt

Bayer data for kidney disease hope finerenone sets up filing...

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the phase 3 FIDELIO-DKD trial.

Janssen taps wearable tech in Invokana heart failure trial

FDA clears cardiovascular claim for J&J’s Invokana

Johnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA approved a new cardiovascular outcome claim on its label.